President Donald Trump signed an executive order Saturday directing federal agencies to accelerate the review and research of psychedelic drugs for treating serious mental health conditions, a move that could open a new pathway for veterans suffering from PTSD, traumatic brain injury, and opioid addiction.
The order, titled "Accelerating Medical Treatments For Serious Mental Illnesses," targets the federal bureaucracy that has kept promising compounds locked behind years of regulatory delay. It directs the Department of Health and Human Services to work with the Department of Veterans Affairs and the private sector to expand clinical trial participation, data-sharing, and real-world evidence on psychedelic treatments.
The signing ceremony brought together an unusual cast: HHS Secretary Robert F. Kennedy Jr., podcaster Joe Rogan, and former Navy SEAL Marcus Luttrell stood alongside the president. The order names ibogaine, a Schedule I substance derived from an African shrub, as a key compound of interest, along with psilocybin, LSD, and MDMA. All four have shown clinical promise for conditions that standard therapies often fail to resolve.
The order's most concrete provision appears in Section 2, which allows the Food and Drug Administration to extend "right to try" provisions to psychedelic drugs, including ibogaine compounds, for patients who meet eligibility criteria and carry certain diagnoses. Right-to-try laws, which Trump championed in his first term, let terminally ill patients access experimental treatments that have not yet completed the full FDA approval process. Applying that framework to psychedelics marks a significant expansion.
The executive order itself states that the FDA has already granted Breakthrough Therapy designation to specific psychedelic drugs and that "numerous products" sit in the clinical trial pipeline awaiting safety and efficacy review. The Daily Caller reported that the order allows psychedelics, including ibogaine, to be researched and used in specific cases, a deliberate step past the status quo, where Schedule I classification has made even basic research painfully slow.
Trump framed the action in plain terms during the ceremony:
"Today's order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life."
AP News reported that the FDA plans to issue national priority vouchers for three psychedelics, a step that could cut review times from months to weeks. The administration also committed at least $50 million to states developing programs to advance psychedelic drugs for serious mental illness, real money behind a policy that could otherwise remain symbolic.
The order explicitly ties its urgency to the national mental health crisis, noting that suicide rates "dramatically increased" during the COVID-19 pandemic and the Biden administration. That framing puts the policy squarely in the context of government failure, years of worsening outcomes despite billions spent on conventional approaches.
Rogan, who has long advocated for psychedelic research on his podcast, laid out the numbers at the ceremony. He cited more than 80,000 overdose deaths in 2024 and more than 5 million Americans currently addicted to opioids. Then he turned to ibogaine specifically:
"With one dose of ibogaine, more than 80% of people are free of that addiction. With two doses, it's more than 90%."
Those are Rogan's figures, and they deserve the scrutiny that any claim about a Schedule I drug warrants. But the broader point, that existing treatments are failing millions of people, and that promising alternatives remain trapped in regulatory limbo, is hard to dispute.
The president has shown a willingness to use executive authority aggressively across a range of policy areas, from voter eligibility requirements to document-disclosure battles. This order fits the pattern: identify a problem the bureaucracy has failed to solve, then use presidential power to force movement.
Veterans' advocates who attended or responded to the signing reinforced the case. Fox News reported that supporters, including veterans' advocates and some doctors, said the move could help veterans with treatment-resistant PTSD and traumatic brain injury when SSRIs and talk therapy have failed. Jay Kopelman, a veterans' advocate, said the president's action "opens a pathway to research that will further open doors to expedited approval of this life-saving medicine as a treatment for our veterans, and society."
Juliana Mercer put it in personal terms:
"I think about veterans I served with, people who have done years of therapy, cycled through medications, and are still carrying the weight of their service."
Rogan described the origin of the order with characteristic directness. He said he sent the president information on the effects of ibogaine on veterans with TBI and PTSD. The response, Rogan told the ceremony audience, came fast:
"The text message came back, 'Sounds great! Do you want FDA approval? Let's do it!' It was literally that quick."
That anecdote will irritate the Washington establishment, which prefers that policy move through layers of interagency review, stakeholder comment, and academic consensus-building. But for veterans who have waited years while the system churned, speed is the point.
The administration has faced legal resistance to several of its executive orders. A federal judge permanently blocked one order targeting NPR and PBS funding, and others have drawn immediate court challenges. Whether this psychedelic-research order faces similar obstacles remains to be seen. Its focus on directing agency priorities and extending existing right-to-try frameworks may give it stronger legal footing than orders that attempt to redirect appropriated funds.
Ibogaine sits in a peculiar regulatory position. It is classified as Schedule I, the most restrictive category, reserved for drugs the government says have no accepted medical use and high abuse potential. That classification has made clinical research extraordinarily difficult, creating a catch-22: the government says there's no proven medical use, but it blocks the research that could prove one.
Breitbart reported that the order could open a pathway for ibogaine, psilocybin, LSD, and MDMA to be used in controlled therapeutic settings. Trump himself said at the signing that the administration would open a pathway for ibogaine to be included in the right-to-try framework.
The executive order acknowledges the existing clinical pipeline directly. It states that psychedelic drugs, "including ibogaine compounds, show potential in clinical studies to address serious mental illnesses for patients whose conditions persist after completing standard therapy." That language matters, it frames psychedelics not as first-line treatments but as options for patients who have already exhausted conventional care.
Trump has shown a pattern of using executive orders to force action when Congress stalls. He has pledged executive action on voter ID if the Senate fails to move, and he has ordered the National Archives to hand over Biden-era documents that Congress demanded. The psychedelic-research order follows the same logic: if the regulatory apparatus won't move on its own, the president will move it.
Trump added a broader note at the ceremony, one that captured the administration's bet on these treatments:
"We're taking this decision, this decisive step, to confront one of the most urgent public health challenges facing our nation, the mental health crisis."
The order leaves several details unresolved. It does not specify which mental health diagnoses qualify patients for the expanded right-to-try provisions. The exact scope of the FDA's new authority under Section 2 remains to be defined through implementation. And ibogaine itself carries known heart-related safety risks that will require careful clinical oversight, a fact even the order's supporters acknowledge.
None of that diminishes the core policy shift. For years, the federal government has watched suicide rates climb, opioid addiction spread, and veterans cycle through treatments that don't work, all while sitting on research suggesting that psychedelic-assisted therapy might help. The regulatory system designed to protect patients has, in this case, also prevented them from accessing potentially life-changing care.
Whether psychedelics ultimately prove as effective as their advocates claim is a question for clinical trials and hard data. What this order does is ensure those trials can actually happen, and that veterans dying while the bureaucracy deliberates might finally get a chance at something different.
When the government spends decades failing the people who fought for it, a little urgency isn't reckless. It's overdue.
